Encapsulation, stability and in-vitro release characteristics of liposomal formulations of colchicine.
The severe toxicity and low therapeutic index of colchicine limit its therapeutic use. Encapsulation in liposomes might reduce these toxic effects. The objective of this study was to determine the factors influencing encapsulation of colchicine in liposomes and to optimize the encapsulation parameters. Colchicine was encapsulated in multilamellar liposomes and large unilamellar liposomes prepared using various phospholipids. The effects of method of preparation, type of vesicle, charge, and concentration of cholesterol on encapsulation of colchicine in liposomes were investigated. Also, stability of colchicine under stress conditions and at various temperatures, and in-vitro release characteristics were determined. A significant difference in encapsulation of colchicine in multilamellar liposomes was observed when prepared by two different methods. Induction of charge on the liposome surface increased encapsulation of colchicine in multilamellar liposomes, but did not affect large unilamellar liposomes. The liposome preparations could withstand simulated transport conditions and frequent changes in temperature. Particle size and concentration of colchicine did not change significantly during storage at various temperatures for six months. In order to retain encapsulated colchicine in liposomes, storage at or below room temperature was found to be suitable. In-vitro release of colchicine from large unilamellar liposomes was biphasic and was influenced by two rate-limiting barriers, the dialysis membrane and the liposome bi-layers. For optimum encapsulation and stability of colchicine liposomes were prepared from a mixture of 1,2-distearoyl-sn-glycero-3-phosphocholine, cholesterol and either stearylamine or dicetyl phosphate.
Kulkarni
S B
SB
Department of Pharmacal Sciences, School of Pharmacy, Auburn University 36849, USA.
Singh
M
M
Betageri
G V
GV
D002214:Capsules; D002626:Chemistry, Pharmaceutical / Q000379:methods; D003078:Colchicine / Q000008:administration & dosage* / Q000737:chemistry* / Q000493:pharmacokinetics; D004337:Drug Carriers; D016503:Drug Delivery Systems; D004355:Drug Stability; D006074:Gout Suppressants / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology*; D008081:Liposomes; D010316:Particle Size
D002214:Capsules; D004337:Drug Carriers; D006074:Gout Suppressants; D008081:Liposomes; D003078:Colchicine